Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Prostate cancer remains a significant health concern.
• Current treatments have limitations, necessitating novel therapeutic approaches.
• Dendritic cell (DC) based vaccines offer a promising avenue for cancer immunotherapy.

Purpose of the Study:

• To evaluate the safety and feasibility of a novel dendritic cell (DC) vaccination strategy for prostate cancer.
• To assess the immunogenicity of DCs transfected with mRNA from allogeneic prostate cancer cell lines.
• To explore the correlation between immune responses and clinical outcomes, including prostate-specific antigen (PSA) levels.

Main Methods:

• A clinical trial involving 20 prostate cancer patients.
• Vaccination with mRNA-transfected allogeneic prostate cancer cell line DCs (DU145, LNCaP, PC-3).
• Administration of at least four weekly injections (intranodal or intradermal) of 2 x 10(7) transfected DCs.
• Monitoring of safety, immune responses (delayed-type hypersensitivity, ELISPOT, T-cell proliferation), PSA levels, and bone scans.

Main Results:

• The vaccination was safe and feasible, with no observed toxicity or serious adverse events.
• 12 out of 19 patients developed specific immune responses to tumor mRNA-transfected DCs.
• 13 patients showed a decrease in log slope PSA, with booster vaccinations enhancing this effect.
• Clinical outcome was significantly correlated with immune responses (P = 0.002, r = 0.68).

Conclusions:

• Vaccination with mRNA-transfected DCs is safe and elicits cellular immune responses specific to prostate cancer antigens.
• The observed effect on PSA levels suggests potential as a therapeutic modality for prostate cancer.
• This approach warrants further investigation as a novel treatment strategy for prostate cancer patients.